Literature DB >> 22825756

[Pityriasis rubra pilaris].

U Wollina1.   

Abstract

Pityriasis rubra pilaris is an inflammatory papulosquamous skin disease of unknown etiology. Incidence rates vary between 1:5,000-1:50,000. Six subtypes are differentiated on clinical background. The juvenile circumscribed subtype has best prognosis. Generalized disease impairs quality of life of patients. It is associated with various complications and comorbidities. Treatment of pityriasis rubra pilaris is challenging. Retinoids are first line drugs. In recalcitrant cases, tumor necrosis factor-α inhibitors have been used successfully.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825756     DOI: 10.1007/s00105-012-2424-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  41 in total

1.  Pityriasis rubra pilaris in identical twins.

Authors:  E A KNUDSEN
Journal:  Br J Dermatol       Date:  1958-01       Impact factor: 9.302

2.  Etanercept-induced clinical remission of type II pityriasis rubra pilaris with rheumatoid arthritis.

Authors:  Jong Hoon Kim; Min-Chan Park; Soo-Chan Kim
Journal:  Acta Derm Venereol       Date:  2012-07       Impact factor: 4.437

3.  Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy.

Authors:  Ricardo Ruiz Villaverde; Daniel Sánchez Cano
Journal:  Eur J Dermatol       Date:  2010-07-07       Impact factor: 3.328

4.  Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy.

Authors:  Yao-Hua Zhang; Youwen Zhou; Nigel Ball; Ming-Wan Su; Jin-Hua Xu; Zhi-Zhong Zheng
Journal:  J Cutan Med Surg       Date:  2010 Jul-Aug       Impact factor: 2.092

5.  Off-label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study.

Authors:  A Klein; B Coras; M Landthaler; P Babilas
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-10-18       Impact factor: 6.166

6.  Treatment of juvenile pityriasis rubra pilaris with etanercept.

Authors:  Veronica Cox; Erin B Lesesky; Barbara D Garcia; Terence C O'Grady
Journal:  J Am Acad Dermatol       Date:  2008-11       Impact factor: 11.527

7.  Familial pityriasis rubra pilaris is caused by mutations in CARD14.

Authors:  Dana Fuchs-Telem; Ofer Sarig; Maurice A M van Steensel; Ofer Isakov; Shirli Israeli; Janna Nousbeck; Katharina Richard; Veronique Winnepenninckx; Marigje Vernooij; Noam Shomron; Jouni Uitto; Philip Fleckman; Gabriele Richard; Eli Sprecher
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

Review 8.  Superantigens. Do they have a role in skin diseases?

Authors:  L Skov; O Baadsgaard
Journal:  Arch Dermatol       Date:  1995-07

9.  Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features.

Authors:  Christine J Ko; Leonard M Milstone; Jaehyuk Choi; Jennifer M McNiff
Journal:  Int J Dermatol       Date:  2011-12       Impact factor: 2.736

10.  Pityriasis rubra pilaris and HIV infection.

Authors:  A Blauvelt; G T Nahass; R J Pardo; F A Kerdel
Journal:  J Am Acad Dermatol       Date:  1991-05       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.